Dexamethasone is a corticosteroid sold in the U.S. under 11 brand and generic names, for addison disease, brain edema and bursitis. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Decadron (application NDA012376). Other dexamethasone products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
For Oral Administration The initial dosage varies from 0.75 mg to 9 mg a day depending on the disease being treated. It Should Be Emphasized That Dosage Requirements Are Variable and Must Be Individualized on The Basis of The Disease Under Treatment and The Response of The Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of dexamethasone for a week followed by 4 mg to 12 mg every other day for one month have been shown to be effective (see PRECAUTIONS , Neuro-psychiatric ). In pediatric patients, the…
(listed alphabetically, under each subsection) The following adverse reactions have been reported with dexamethasone or other corticosteroids: Allergic Reactions: Anaphylactoid reaction, anaphylaxis, angioedema. Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS, Cardio-renal ), edema, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. Dermatologic: Acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, hyperglycemia, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients. Fluid and Electrolyte Disturbances: Congestive heart failure in…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Topical | Generic | $0 | View → | |
| 2 | 72/100 | Prescription | Tablet | Generic |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| 54;960 | 0.75 mg | blue | round | — |
| 54;892 | 4 mg | green | round | — |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Dexamethasone Sodium Phosphate Injection
Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.
SOMERSET THERAPEUTICS LLC · Feb 4, 2026
Dexamethasone Moxifloxacin
Presence of particulate matter - Glass like particles.
Imprimis NJOF, LLC · Dec 18, 2025
Dexamethasone Moxifloxacin Ketorolac
Presence of particulate matter - Glass like particles.
Imprimis NJOF, LLC · Dec 18, 2025
Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension Rx Only
Temperature Abuse
Sandoz Inc · Aug 13, 2025
Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL)
Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.
Nubratori, Inc · Apr 15, 2025
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Systemic fungal infections (see WARNINGS , Fungal infections ). Dexamethasone tablets are contraindicated in patients who are hypersensitive to any components of this product.
| $0 |
| View → |
| 3 | 72/100 | Prescription | Injectable | Generic | $0 | View → |
| 4 | 70/100 | Prescription | Spray/Inhaler | Generic | $0 | View → |
| 5 | 70/100 | Prescription | Implant | Generic | $0 | View → |
| 6 | Not yet rated | Prescription | Elixir | Generic | $0 | View → |
| 7 | Not yet rated | Prescription | Injectable | Generic | $0 | View → |
| 8 | Not yet rated | Prescription | Insert | Generic | $0 | View → |
| 9 | Not yet rated | Prescription | Injectable | Generic | $0 | View → |
| 10 | Not yet rated | Prescription | Tablet | Generic | $0 | View → |